Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia

Journal of Clinical Oncology

Volumn 33, Issue 35, 2015, Pages 4210-4218

  Moslehi, Javid J ^a   Deininger, Michael ^b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; BOSUTINIB; DASATINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; IMATINIB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; IMIDAZOLE DERIVATIVE; NITRILE; PROTEIN KINASE INHIBITOR; PYRIDAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE;

ANTICOAGULANT THERAPY; BCR ABL1 GENE; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; GENE; GENE MUTATION; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR SYSTEM; CHEMICALLY INDUCED; DRUG EFFECTS; HYPERTENSION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULARLY TARGETED THERAPY;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS AS TOPIC; DASATINIB; FUSION PROTEINS, BCR-ABL; HUMANS; HYPERTENSION; IMATINIB MESYLATE; IMIDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR TARGETED THERAPY; NITRILES; PROTEIN KINASE INHIBITORS; PYRIDAZINES; PYRIMIDINES; QUINOLINES;

EID: 84957552953     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.4718     Document Type: Review

References (83)

1. López-Otín C, Hunter T: The regulatory cross-talk between kinases and proteases in cancer. Nat Rev Cancer 10:278-292, 2010
2. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
3. Druker BJ, Guilhot F, O'Brien SG, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006
4. Gambacorti-Passerini C, Antolini L, Mahon FX, et al: Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103:553-561, 2011
5. Larson RA, Hochhaus A, Hughes TP, et al: Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 26:2197-2203, 2012
6. Jabbour E, Kantarjian HM, Saglio G, et al: Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123:494-500, 2014
7. Cortes JE, Kim DW, Kantarjian HM, et al: Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Results from the BELA trial. J Clin Oncol 30:3486-3492, 2012
8. Cortes JE, Kim DW, Pinilla-Ibarz J, et al: A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369:1783-1796, 2013
9. Cortes JE, Kantarjian H, Shah NP, et al: Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 367:2075-2088, 2012
10. Goodrich AD: Ponatinib in the leukemia world: Why a reevaluation is necessary for Philadelphia chromosome-positive patients with T315I mutation. Expert Rev Hematol 7:513-515, 2014
11. Mahon FX, Réa D, Guilhot J, et al: Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029-1035, 2010
12. Ross DM, Branford S, Seymour JF, et al: Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study. Blood 122:515-522, 2013
13. Takahashi N, Kyo T, Maeda Y, et al: Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica 97:903-906, 2012
14. Uitdehaag JC, de Roos JA, van Doornmalen AM, et al: Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use. PLoS One 9:e92146, 2014
15. Rix U, Hantschel O, DürnbergerG, et al: Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib reveal novel kinase and non-kinase targets. Blood 110:4055-4063, 2007
16. ChamrádI, Rix U, Stukalov A, et al: A miniaturized chemical proteomic approach for target profiling of clinical kinase inhibitors in tumor biopsies. J Proteome Res 12:4005-4017, 2013
17. O'Hare T, Zabriskie MS, Eiring AM, et al: Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 12:513-526, 2012
18. Deininger MW, Manley P: What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML? Leuk Res 36:253-261, 2012
19. Aichberger KJ, Herndlhofer S, Schernthaner GH, et al: Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 86:533-539, 2011
20. Giles FJ, Mauro MJ, Hong F, et al: Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: A retrospective cohort analysis. Leukemia 27:1310-1315, 2013
21. Montani D, Bergot E, Günther S, et al: Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125:2128-2137, 2012
22. Valent P, Hadzijusufovic E, Schernthaner GH, et al: Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood 125:901-906, 2015
23. Buchdunger E, Zimmermann J, Mett H, et al: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100-104, 1996
24. Heinrich MC, Griffith DJ, Druker BJ, et al: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96:925-932, 2000
25. van Oosterom AT, Judson I, Verweij J, et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358:1421-1423, 2001
26. O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003
27. Kerkelä R, Grazette L, Yacobi R, et al: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908-916, 2006
28. Atallah E, Kantarjian H, Cortes J: In reply to "Cardiotoxicity of the cancer therapeutic agent imatinib mesylate." Nat Med 13:14, 2007
29. Gambacorti-Passerini C, Tornaghi L, Franceschino A, et al: In reply to "Cardiotoxicity of the cancer therapeutic agent imatinib mesylate." Nat Med 13:13-14,2007
30. Hatfield A, Owen S, Pilot PR: In reply to "Cardiotoxicity of the cancer therapeutic agent imatinib mesylate." Nat Med 13:13, 2007
31. Rosti G, Martinelli G, Baccarani M: In reply to "Cardiotoxicity of the cancer therapeutic agent imatinib mesylate." Nat Med 13:15, 2007
32. Saglio G, Kim DW, Issaragrisil S, et al: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251-2259, 2010
33. Estabragh ZR, Knight K, Watmough SJ, et al: A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib. Leuk Res 35:49-51, 2011
34. Atallah E, Durand JB, Kantarjian H, et al: Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 110:1233-1237, 2007
35. Trent JC, Patel SS, Zhang J, et al: Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer 116:184-192, 2010
36. Wolf A, Couttet P, Dong M, et al: Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. Leuk Res 34:1180-1188, 2010
37. Tiribelli M, Medeot M: Cardiotoxicity of imatinib: At the heart of the problem. Leuk Res 35:36-37, 2011
38. Louvet C, Szot GL, Lang J, et al: Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A 105:18895-18900, 2008
39. Lassila M, Allen TJ, Cao Z, et al: Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol 24:935-942, 2004
40. Mariani S, Tornaghi L, Sassone M, et al: Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia. Leuk Res 34:e5-e7, 2010
41. Veneri D, Franchini M, Bonora E: Imatinib and regression of type 2 diabetes. N Engl J Med 352:1049-1050, 2005
42. Breccia M, Muscaritoli M, Aversa Z, et al: Imatinib mesylate may improve fasting blood glucose in diabetic Pho+ chronic myelogenous leukemia patients responsive to treatment. J Clin Oncol 22:4653-4655, 2004
43. Schermuly RT, Dony E, Ghofrani HA, et al: Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115:2811-2821, 2005
44. Hoeper MM, Barst RJ, Bourge RC, et al: Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: Results of the randomized IMPRES study. Circulation 127:1128-1138, 2013
45. Shah AM, Campbell P, Rocha GQ, et al: Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension. Eur Heart J 36:623-632, 2015
46. Kantarjian HM, Shah NP, Cortes JE, et al: Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119:1123-1129, 2012
47. Talpaz M, Shah NP, Kantarjian H, et al: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354:2531-2541, 2006
48. Mattei D, Feola M, Orzan F, et al: Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 43:967-968, 2009
49. Shepherd J: FDA drug safety podcast for healthcare professionals: Sprycel (dasatinib) and risk of pulmonary arterial hypertension - US Food and Drug Administration. http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm275517.htm
50. le Coutre PD, Hughes TP, Mahon F-X, et al: Peripheral arterial occlusive disease (PAOD) in patients (Pts) receiving dasatinib: Experience across multiple clinical trials. Blood 122:1489, 2013 (abstr)
51. Cortes JE, Saglio G, Baccarani M, et al: Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056). Blood 124:152, 2014 (abstr)
52. Kantarjian H, Giles F, Wunderle L, et al: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542-2551, 2006
53. Kim TD, le Coutre P, Schwarz M, et al: Clinical cardiac safety profile of nilotinib. Haematologica 97:883-889, 2012
54. Breccia M, Loglisci G, Salaroli A, et al: Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index. Leuk Res 36:e66-e67, 2012
55. Rea D, Mirault T, Cluzeau T, et al: Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica 99:1197-1203, 2014
56. Le Coutre P, Rea D, Abruzzese E, et al: Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst 103:1347-1348, 2011
57. Larson RA, Kim D-W, Issaragrilsil S, et al: Efficacy and safety of nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Long-term follow-up (f/u) of ENESTnd. https://ash.confex.com/ash/2014/webprogram/Paper69226.html
58. Quintás-Cardama A, Kantarjian H, Cortes J: Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk 12:337-340, 2012
59. Levato L, Cantaffa R, Kropp MG, et al: Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: A single institution study. Eur J Haematol 90:531-532, 2013
60. Kim TD, Rea D, Schwarz M, et al: Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 27:1316-1321, 2013
61. Hirsch AT, Haskal ZJ, Hertzer NR, et al: ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): Executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 47:1239-1312, 2006
62. Faxon DP, Creager MA, Smith SC Jr, et al: Atherosclerotic Vascular Disease Conference: Executive summary - Atherosclerotic Vascular Disease Conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 109:2595-2604, 2004
63. Hirsch AT, Duval S: The global pandemic of peripheral artery disease. Lancet 382:1312-1314, 2013
64. European Medicines Agency: Summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000798/WC500034394.pdf
65. Brümmendorf TH, Cortes JE, de Souza CA, et al: Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: Results from the 24-month follow-up of the BELA trial. Br J Haematol 168:69-81, 2015
66. Bair SM, Choueiri TK, Moslehi J: Cardiovascular complications associated with novel angiogenesis inhibitors: Emerging evidence and evolving perspectives. Trends Cardiovasc Med 23:104-113, 2013
67. Kantarjian HG, Kim D-W, Pinilla-Ibarz J, et al: Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Pho+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial. J Clin Oncol 32, 2014 (suppl 5s; abstr 7081)
68. Knickerbocker R, Dorer DJ, Haluska FG, et al: Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. https://ash.confex.com/ash/2014/webprogram/Paper67858.html
69. Mauro MJ, Cortes JE, Hochhaus A, et al: Ponatinib efficacy and safety in patients with the T315I mutation: Long-term follow-up of phase 1 and phase 2 (PACE) trials. Blood 124:4552, 2014 (abstr)
70. Zhu X, Stergiopoulos K, Wu S: Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis. Acta Oncol 48:9-17, 2009
71. Wu S, Chen JJ, Kudelka A, et al: Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis. Lancet Oncol 9:117-123, 2008
72. O'Hare T, Shakespeare WC, Zhu X, et al: AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16:401-412, 2009
73. Fernández A, Sanguino A, Peng Z, et al: An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest 117:4044-4054, 2007
74. Groarke JD, Cheng S, Moslehi J: Cancer-drug discovery and cardiovascular surveillance. N Engl J Med 369:1779-1781, 2013
75. Loren CP, Aslan JE, Rigg RA, et al: The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear. Thromb Res 135:155-160, 2015
76. Emir H, Albrecht-Schgoer K, Huber K, et al: Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells: A potential explanation for drug-induced vasculopathy in CML. Blood 122:257, 2013 (abstr)
77. Yusuf S, Hawken S, Ounpuu S, et al: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 364:937-952, 2004
78. Moslehi J: The cardiovascular perils of cancer survivorship. N Engl J Med 368:1055-1056, 2013
79. Warfarin Antiplatelet Vascular Evaluation Trial Investigators, Anand S, Yusuf S, et al: Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 357:217-227, 2007
80. Hsu S, Ton VK, Dominique Ashen M, et al: A clinician's guide to the ABCs of cardiovascular disease prevention: The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative. Clin Cardiol 36:383-393, 2013
81. Montazeri K, Unitt C, Foody JM, et al: ABCDE steps to prevent heart disease in breast cancer survivors. Circulation 130:e157-e159, 2014
82. O'Brien S, Furman RR, Coutre SE, et al: Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b/2 trial. Lancet Oncol 15:48-58, 2014
83. Byrd JC, O'Brien S, James DF: Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:1278-1279, 2013